AI Article Synopsis
- - The text discusses the potential of immune checkpoint inhibitors (ICIs) to treat various cancers, but highlights the lack of solid clinical trial data on their safety and effectiveness in patients with preexisting autoimmune diseases due to concerns over severe side effects.
- - It reports a case of a patient experiencing a life-threatening flare-up of systemic lupus erythematosus after receiving pembrolizumab, an ICI, as part of chemo-immunotherapy for non-small-cell lung cancer.
- - The authors analyze existing literature on this issue and weigh the risks and benefits of using immunotherapy in cancer patients who have serious autoimmune conditions.
Article Abstract
The use of immune checkpoint inhibitors (ICIs) offers new possibilities in modern treatment of many types of cancers. Few data regarding safety and efficacy of ICIs are available, and are mainly from retrospective studies and case reports rather than from clinical trials, in the context of preexisting autoimmune disease, mainly due to the risk of severe toxicity. We present an unexpected life-threatening reactivation of systemic lupus erythematosus after one dose of chemo-immunotherapy with pembrolizumab for oligometastatic non-small-cell lung cancer. We analyze data coming from the published literature in this setting and discuss the risk-benefit balance of immunotherapy in patients with preexisting severe autoimmune disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/03008916211067565 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!